Kairos Pharma, LTD.
KAPA evidence brief
What we can confirm
- Market Cap:
- $6.0M
What it means
What to watch
Prepared research question
What matters most for KAPA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KAPA
Kairos Pharma, LTD. (KAPA) is a pre-revenue biotech company developing novel drugs targeting drug resistance and immune suppression checkpoints, with no FDA-approved products and significant operating losses.
Key risk: No revenue or approved products
Market Cap
$6.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials for Kairos Pharma, LTD..
Kairos Pharma, LTD. (KAPA) is a pre-revenue biotech company developing novel drugs targeting drug resistance and immune suppression checkpoints, with no FDA-approved products and significant operating losses.
- Kairos Pharma has no products approved for sale and has not generated any revenue from product sales [sec_mda · as of 2026-08-12].
- Cash & equivalents were $2.6M as of 2026-06-30 [sec].
- Net income was -$1.4M for the period ending 2026-06-30 [sec].
- Shareholders' equity was $4.2M as of 2026-06-30 [sec].
- The company expects expenses to increase substantially as it advances product candidates through clinical trials [sec_mda · as of 2026-08-12].
What works
- Kairos Pharma is developing a new class of novel drugs designed to target drug resistance and checkpoints of immune suppression, which may address significant unmet medical needs [sec_mda · as of 2026-08-12].
- The company has initiated clinical trials, including a Phase 1 study for axicabtagene ciloleucel in relapsed/refractory large B-cell lymphoma and Phase 2 studies for FKC289 in AL amyloidosis and membranous nephropathy [catalyst].
- Management estimates that current cash resources will fund planned expenses and capital expenditure requirements for at least the next 12 months from the date of filing of the August 2026 report [sec_mda · as of 2026-08-12].
What to weigh
- Kairos Pharma has no products approved for sale and has not generated any revenue from product sales since inception [sec_mda · as of 2026-08-12].
- The company has incurred significant operating losses, with net losses of $3,042 (in thousands) for the period reported in the August 2026 filing [sec_mda · as of 2026-08-12].
- The successful development and commercialization of product candidates is highly uncertain due to numerous risks, including clinical trial outcomes, regulatory approval, and funding [sec_mda · as of 2026-08-12].
- The company may exhaust available capital resources sooner than expected if assumptions about expenses and timelines prove wrong [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
No approved products or revenue from product sales
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · August 12, 2026
Novel drug class targeting drug resistance and immune suppression
“a new class of novel drugs that are designed to target drug resistance and checkpoints of immune suppression.”
SEC MD&A · August 12, 2026
Significant operating losses incurred
“Since inception, we have incurred significant operating losses.”
SEC MD&A · August 12, 2026
Uncertainty in product development and commercialization
“The successful development and commercialization of product candidates is highly uncertain.”
SEC MD&A · August 12, 2026
Catalyst timeline
- 2026-06-12 · Phase 1 Start for axicabtagene ciloleucel in relapsed/refractory large B-cell lymphoma — A single-arm, multicenter study evaluating efficacy and safety of an automated manufacturing process for this CAR-T therapy.
- 2026-08-01 · Phase 2 Start for FKC289 in relapsed/refractory primary AL amyloidosis — Open-label, single-arm, multicenter study to evaluate safety and efficacy of FKC289 in this patient population.
- 2026-08-01 · Phase 2 Start for FKC289 in relapsed/refractory membranous nephropathy — Open-label, single-arm, multicenter study to evaluate safety and efficacy of FKC289 in this kidney disease indication.
Risks & what to watch (4)›
Key risks
- No revenue or approved products — Company has no approved products and no revenue from product sales since inception [sec_mda · as of 2026-08-12].
- Significant operating losses — Net losses were $3,042 (in thousands) for the period reported in August 2026 filing [sec_mda · as of 2026-08-12].
- Clinical and regulatory uncertainty — Development and commercialization of product candidates is highly uncertain due to clinical, regulatory, and funding risks [sec_mda · as of 2026-08-12].
- Potential capital shortfall — Company may exhaust available capital resources sooner than expected if assumptions are wrong [sec_mda · as of 2026-08-12].
What to watch
- Progress and results of the Phase 1 clinical study for axicabtagene ciloleucel in relapsed/refractory large B-cell lymphoma [catalyst].
- Initiation and outcomes of Phase 2 studies for FKC289 in AL amyloidosis and membranous nephropathy [catalyst].
- Cash runway and ability to raise additional funds as expenses increase with clinical development [sec_mda · as of 2026-08-12].
- Any updates on regulatory interactions or FDA feedback on product candidates [sec_mda · as of 2026-08-12].
Sources: Catalysts · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Kairos Pharma, LTD. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kairos Pharma, LTD. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 0.9%
- Days to cover
- 1.4
- Shares short
- 125,693
- Daily short volume (May 4, 2026)
- 12.6%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KAPA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Kairos Pharma, LTD.?
Kairos Pharma, LTD. (KAPA) is a pre-revenue biotech company developing novel drugs targeting drug resistance and immune suppression checkpoints, with no FDA-approved products and significant operating losses.
Who is the CEO of Kairos Pharma, LTD.?
Dr. John S. Yu M.D., Ph.D. is the chief executive officer of Kairos Pharma, LTD. (KAPA).
Where is Kairos Pharma, LTD. headquartered?
Kairos Pharma, LTD. (KAPA) is headquartered in Los Angeles, CA, United States.
What therapeutic areas does Kairos Pharma, LTD. focus on?
Kairos Pharma, LTD. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.